Company: ZVRA
Filing Date: 2025-04-23
Form Type: DFAN14A
Source: 0000897069-25-000852
Chunk: 1

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: DFAN14A
Chunk 1
---
 Mangless has nominated Travis C. Mickle, PhD and Arthur C. Regan as nominees to the Company’s board of directors (the “ Nominees”) and intends to solicit votes for the election of the Nominees as members of the Company’s board of directors. Mr. Mangless will send a definitive proxy statement, BLUEproxy card and related proxy materials to shareholders of the Company seeking their support of the Nominees at the Company’s 2025 annual meeting of stockholders. Stockholders are urged to read the definitive proxy statement and BLUE proxy card when they become available, because they will contain important information about the Nominees, the Company and related matters.Shareholders may obtain a free copy of the definitive proxy statement and BLUEproxy card (when available) and other documents filed by Mr. Mangless with the Securities and Exchange Commission (“ SEC”) at the SEC’s web site at www.sec.gov. Shareholders may also direct a request to Mr. Mangless’ proxy solicitor, Regan & Associates, Inc., 505 Eighth Avenue, Suite 800, New York, NY 10018 (shareholders can e-mail at main@reganproxy.com or call toll-free at (800) 737-3426). Participants in Solicitation Daniel J. Mangless together with Travis C. Mickle, PhD and Arthur C. Regan (the “ Mangless Group”) are the participants in the solicitation by Mr. Mangless. The participants may have interests in the solicitation, including as a result of holding shares of the Company’s common stock. Mr. Mangless filed an amended preliminary proxy statement under cover of Schedule 14A on April 16, 2025 (the “ Preliminary Proxy Statement”). Information regarding the participants and their interests is contained in the Preliminary Proxy Statement. 2 3 4 5 6 7 8 9 10 11 12 13

<div align='center'>14</div>